The maintenance of an Equal-Weight rating and a steady price target by a major analyst like Morgan Stanley suggests a neutral short-term impact on Clorox's stock. The reaffirmation indicates that the analyst sees no immediate catalysts that would significantly change the company's valuation or stock performance in the near term. Therefore, the impact is neutral, reflecting stability in the analyst's outlook.